edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Healthcare
Biomea Fusion announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials, COVALENT-111 and COVALENT-112, for BMF-219, which is being evaluated as a potential new treatment for type 2 and type 1 diabetes, respectively. BMF-219 is Biomea Fusion’s lead asset and it has potential as a first-in-class agent for the treatment of diabetes, operating by a novel covalent mechanism of action. Top-line data readouts for COVALENT-111 and COVALENT-112 remain on track for Q424.
Industrials | Comment
Industrials | Comment
Industrials | Comment
Consumer | Comment
Get access to the very latest content matched to your personal investment style.